

CAL-101 (Idelalisib, GS-1101)

CAL-101 (Idelalisib, GS-1101, Zydelig) is a synthetic drug that potently inhibits the phosphoinositide 3-kinase P110 δ (IC₅₀=2.5nM), with 40-300-fold selectivity over p110 α , β , and γ . FDA approved for treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab.

Materials Provided

Catalog Number:	92-1258
Quantity Supplied:	1 vial(s), 10 mg per vial

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

Molecular Weight:	415.41 g/mol
Source:	Synthetic
Purity:	≥ 99%
Endotoxin Level:	N/A
Formulation:	N/A
Storage:	-20°C Please avoid multiple freeze/thaw cycles.

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

Stock Concentration:	50 mM
Reconstitution Volume:	0.481 mL
Reconstitution Solvent:	DMSO

For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com
General product information: www.discoverx.com